Indication: Diffuse Large B-cell Lymphoma
Title: DLBCL/SADAL: A Phase 2b Open-label Study of selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Drug: selinexor

SADAL is an open label, Phase 2b study evaluating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue.

Please visit for more information about this study

This trial is for selinexor.


Drug: selinexor

PreclinicalPhase IPhase IIPhase III
Phase I
Phase II
Phase III